This is a standalone, locally-served educational resource on clinical aromatherapy and phytotherapy, built from a Coursera course outline and subjected to two rounds of independent GPT-5.5 evidence review, a 25-claim factual audit, and a route-specific pharmacology revision. It is not accredited, not certified, and not medical advice. This document records what the course does well, what it gets wrong, and what it is still missing.
The course is stronger than most publicly available aromatherapy education in several specific ways:
Two independent GPT-5.5 curriculum reviews (saved in evidence/) identified material factual problems in the initial build. The most serious corrections:
| Issue | Original wording | Correction | Status |
|---|---|---|---|
| Linalool / GABA-A overclaim | "binds the same benzodiazepine site as Valium" | Flumazenil-sensitive mouse behavioral finding; does not prove direct binding or human equivalence | Fixed |
| Silexan route conflation | Oral Silexan evidence used to support inhaled lavender | Oral standardized product separated from inhalation/topical throughout | Fixed |
| Peppermint in Egypt | "found in Egyptian pyramids, 1550 BCE" | Removed; peppermint is a hybrid, species-level claim unsupported | Fixed |
| Sweet orange phototoxicity | Labeled "mildly phototoxic" | Corrected to non-phototoxic per Tisserand Institute; UI tag removed | Fixed |
| Spearmint / PCOS | Topical EO implication for hirsutism | Removed; evidence is oral tea only, not topical EO | Fixed |
| Roman vs German chamomile | CTS trials (Matricaria chamomilla) cited for Roman chamomile | Botanical identity corrected; CTS evidence removed from Roman chamomile | Fixed |
| Boswellia / frankincense EO | Resin extract research presented as frankincense aromatherapy | Material identity distinction added; extract is not EO | Fixed |
| Blood-brain barrier bypass | "molecules reach the brain within seconds, bypassing the BBB" | Replaced with olfactory receptor signaling language | Fixed |
| Bath safety | Epsom salts, carrier oil, milk described as EO solubilizers | Removed; only validated solubilizer/emulsifier recommended | Fixed |
| Capstone peer review | Static app claimed to perform peer review | Corrected; peer review is conditional on instructor-led LMS delivery | Fixed |
| CE credit claim | "15 contact hours, Minnesota Board of Nursing" | Removed; replaced with standalone-resource disclaimer | Fixed |
This is a dated implementation record. It does not change the historical 30 July independent-review score of 6/10 or replace a new independent re-review.
| Date | Change | Evidence / verification | Status |
|---|---|---|---|
| 31 Jul 2026 | Added evidence-first tea tree and ginger monographs with route-specific sources, explicit negative findings, and no generic raw-oil dosing instructions. | Tea tree keeps the negative ICU MRSA-colonization trial visible; ginger separates limited inhalation evidence from oral ginger evidence. | Implemented; re-review pending |
| 30 Jul 2026 | Evidence-governance revision recorded: route separation, high-risk claim registry, source library, and initial safety corrections. | Historical independent GPT-5.5 review and post-fix re-review; score remained 6/10, revise and resubmit. | Historical |
| 31 Jul 2026 | Added a Module 1 essential-oil chemistry primer; added policy-controlled dilution mathematics and scope/consent teaching. | Source strings and rendered sections checked; calculation guidance deliberately does not teach learner-generated pediatric dosing. | Implemented |
| 31 Jul 2026 | Aligned Module 3 bath explanation, safety list, and quiz feedback; added regression checks for bath solubilizer guidance and mechanism overclaims. | Automated audit plus rendered-course inspection. | Implemented |
| 31 Jul 2026 | Expanded every existing monograph's “What the evidence does not show” panel with an explicit null result, limitation, or route/species non-transferability; added six primary/review sources. | Automated audit now requires an explicit negative, null, or non-transferability limitation for every Module 4/5 monograph. | Implemented; re-review pending |
The original review's priorities are retained below as history, with their current implementation state. The remaining work is ranked by impact on educational completeness.
Implementation note: Module 1 now introduces constituent families, functional groups, GC/MS limits, and cautious structure-safety relationships. This foundation still needs independent appraisal and later oxidation/stability expansion.
Why it matters: The course names constituents inside monographs but never teaches the systematic framework: monoterpene alcohols vs esters vs ketones vs aldehydes vs phenols vs oxides, and why functional groups predict safety properties (phenols are irritants, aldehydes are sensitizers, esters are gentle, ketones carry neurotoxicity concerns). A pharmacognosy course without a dedicated chemistry section is like teaching pharmacology without receptor families.
Effort: New section in Module 1 or a standalone Module 1.5. Requires researched content but no new architecture.
Implementation note: Every Module 4/5 monograph now has an explicit negative, null, or non-transferability statement in its rendered “What the evidence does not show” panel. The automated audit enforces that minimum; it is not a substitute for a full systematic review.
Why it matters: Every monograph presents positive or promising findings. A trustworthy course needs explicit "what didn't work" sections — the RCTs where lavender didn't outperform placebo, the peppermint studies that showed no significant difference, the meta-analyses with high risk of bias. Without this, the course reads as advocacy rather than appraisal. The independent GPT-5.5 reviewer flagged this twice.
Effort: Add a "Limitations and Null Findings" callout to each monograph. Requires targeted literature search for disconfirming studies per oil.
Why it matters: Tea tree (Melaleuca alternifolia) is arguably the second most clinically important EO after lavender — widely used in wound care, MRSA decolonization research, and dermatology. Ginger (Zingiber officinale) has some of the strongest evidence for nausea, and the nausea module omits it entirely. Both omissions are conspicuous in a clinical course.
Effort: Two new monographs with the full evidence-first field set. Requires research but the data structure already exists.
Implementation note: Module 2 now teaches volume-based percentage calculations and policy-first documentation. It explicitly rejects drop-count and learner-generated pediatric weight-based dosing as clinical dosing methods; approved local policy must control special-population protocols.
Why it matters: Module 2 has a dilution table but never teaches how to calculate: drops per carrier volume, percentage conversions, maximum daily exposure for body weight, pediatric weight-based dosing, or how to work backward from a maximum safe concentration to a recipe. A nurse who can't calculate a 0.5% dilution for a 12 kg child isn't safe to practice.
Effort: New section in Module 2 or 3 with worked examples and quiz items. Mostly arithmetic; no new architecture.
Implementation note: Module 2 now addresses scope, consent, truthful representation, local policy, and when to refer or avoid offering an intervention. Jurisdiction-specific examples remain future work.
Why it matters: The learning objectives say "identify safety and ethical issues" but the course never systematically addresses: scope of practice boundaries, informed consent language, when aromatherapy is inappropriate, cultural respect vs appropriation, truth-in-advertising constraints, and the ethics of offering unproven interventions to vulnerable patients (oncology, pregnancy, palliative).
Effort: New section or module. Requires some research into professional codes (ANA, NCBTMB, IFRA) but no new technical architecture.
Why it matters: A clinical course typically covers 12-20 oils. The current formulary has 9. Missing: eucalyptus (respiratory), rosemary (cognitive/circulatory), German chamomile (more clinical trial data than Roman), helichrysum (wound care), clary sage (obstetric), rose (anxiety/skin), oregano or thyme (antimicrobial — referenced in cutting-edge but no monograph).
Effort: Each oil is a full monograph with evidence-first fields. Can be batched. Tea tree and ginger are prioritized above; the rest can follow.
Why it matters: Palliative/end-of-life care is one of the most established clinical aromatherapy settings — anxiety, terminal agitation, sleep, family comfort, scent memories. Preoperative anxiety reduction is one of the best-studied single applications (lavender inhalation RCTs). Both are mentioned in passing but neither gets dedicated treatment.
Effort: Two new sections (or expansion of existing modules). Requires targeted literature review.
Why it matters: Why oxidized limonene becomes a potent sensitizer, how to store oils, shelf life, and how to identify oxidized product — this is safety-critical and not systematically taught. Module 2 mentions GC/MS as a quality tool but doesn't teach how to read a chromatogram or spot adulteration markers.
Effort: Expansion of Module 2 quality section. Partially researched; some content exists in the safety literature.
First, obtain an independent re-review of the 31 July chemistry, safety, dilution, and monograph-limitations work. Second, replace remaining weak citations and reconcile the source library, claim registry, and rendered strings. Third, add tea tree and ginger before broad formulary expansion. The historical phase list below is retained for traceability and must be read with the implementation notes above.
The following phase list is retained as the 30 July recommendation. Items marked implemented above are no longer open work.
status fields with actual revision state.| Oil | Module | Current Status | Priority |
|---|---|---|---|
| Lavender | 4 (Pain/Anxiety) | Complete | — |
| Sweet Orange | 4 | Complete | — |
| Bergamot | 4 | Complete | — |
| Sweet Marjoram | 4 | Complete | — |
| Roman Chamomile | 4 | Complete | — |
| Peppermint | 5 (Nausea/Fatigue) | Complete | — |
| Spearmint | 5 | Complete | — |
| Lemon | 5 | Complete | — |
| Grapefruit | 5 | Complete | — |
| Tea Tree | 4 (topical-evidence case study) | Complete | Re-review |
| Ginger | 5 (Nausea/Fatigue) | Complete | Re-review |
| Eucalyptus | New or 4 | Missing | P2 |
| Rosemary | New or 4 | Missing | P2 |
| German Chamomile | 4 | Missing | P2 |
| Helichrysum | New | Missing | P2 |
| Clary Sage | New or 4 | Missing | P2 |
| Rose | New | Missing | P2 |
| Oregano / Thyme | New | Missing | P2 |
needs-source (grapefruit RCT, marjoram pregnancy direct evidence, pharmacogenomics). They are retained as explicitly cautious; content does not assert unsupported facts.status field is stale for some entries (content has been revised but the status still says revise). The implementationStatus field tracks the actual revision state.